Transcript
Page 1: CONTACT: Sabrina Danilin sabrina.danilin@firalis.com WATCH...S.Danilin, G. Bilger, H Firat, E. Schordan, Firalis SAS, Huningue, France Conclusion Firalis, elading rgoup ni Biomarker

POSTER SESSION: Molecular Diagnostics, April 12-13, 201718340 Yorba Linda Blvd. Ste 107PMB 427, Yorba Linda, CA 92886

LabRoots Corporation © 2017

T +1.714.463.4673F +1.714.970.2173

[email protected] • labroots.com

Valida&on  of  our  HTG  EdgeSeq  Pla6orm  for  accurate  and  sensi&ve  biomarker  discovery  

S.Danilin, G. Bilger, H Firat, E. Schordan, Firalis SAS, Huningue, France

Conclusion    

Firalis,  leading  group  in  Biomarker  discovery  and  qualifica&on  validates  its  next  genera&on  gene  expression  HTG  EdgeSeq  pla6orm  at  its  site  in  Huningue,  France.  

Vast  field  of  exper&se   Exper&se  from  discovery  to  market   State  of  the  art  tools  

Simple  workflow  

Sensi&ve  chemistry  

Minimal  sample  input   HTG  EdgeSeq  technology  

8 patient samples were analyzed using both HTG WTA miRNA panel and qPCR Exiqon miRNA panel V4 (341 miRNA in common).

Results show a good correlation between both methods.

HTG  edgeseq  offers  accurate  results    

HTG  edgeseq  offers  high  reproducibility  

Comparison between 4 independant experiments (sets) on the same sample using the miRNA WTA assay

Sets 1,2,3 : HTG (Tucson, USA) with different instruments/days/operators

Set 4 : Firalis, (Huningue, France)

HTG  mean  by  miRNA  0                          2                            4                          6                          8                        10                      12    

qPCR

 mea

n  by

 miR

NA

 40

           

           

           

35      

           

           

       3

0        

           

           

 25  

           

           

           

 20  

Sample   correla&on  

Set1/Set2   0.999  

Set1/Set3   0.998  

Set2/Set3   0.999  

Set3/Set4   0.993  

Extrac&on  free  Eliminates biases from RNA

extracition Sensi&vity  of  next  genera&on    sequencing  

Various  panels  are  available  

WTA  assay  :  a  study  example  Project outlines -  Validation of miRNAs with predictive value previously identified. -  Samples: 15 µl of plasma from 75 patients with negative outcome and 67 patients with positive

outcome. -  Screening of miRNAs 24 control with HTG EdgeSeq WTA

Results: -  313 miRNAs are above the threshold in plasma samples. -  Predictive value of selected miRNAs confirmed and new miRNAs identified.

!  HTG Edgeseq platform available at Firalis offers a new cost effective and reliable tool for accurate and sensitive RNA expression measurement.

!  Its low sample input requirements and extraction free process make it an invaluable tool for biomarker discovery.  

Contact  :  [email protected]  

Conclusion  

2084  miRNAs  (miR20  database)  

Oncology  biomarkers  

Whole  transcriptome  miRNA  assay  24  HK  

Immuno-­‐onco  drug  response  and  immuno  response  

Lymphoma-­‐associated  genes  assay  

WATCH: Poster Presentation https://youtu.be/eQBS0jGinwI CONTACT: Sabrina Danilin [email protected]

Top Related